https://www.selleckchem.com/products/art558.html
In addition to the main CBMA, we will conduct several supplementary analyses to test the robustness of the results, such as jackknife analyses, subgroup analyses, heterogeneity analyses, publication bias analyses, and meta-regression analyses. This CBMA will offer the latest evidence of CTh alterations in PD. Consistent and robust evidence of CTh alterations will feature brain morphometry of PD and may facilitate biomarker development. CRD42020148775. CRD42020148775. Till date only a few studies have reported the efficacy and clinical im
Like
Comment
Share
